26 / 50
Page 94
Notes:
conferenceseries
.com
Volume 8, Issue 3 (Suppl)
J Clin Cell Immunol, an open access journal
ISSN: 2155-9899
Euro Immunology 2017
June 29-July 01, 2017
June 29-July 01, 2017 Madrid, Spain
8
th
European
Immunology Conference
Ectopic expression of the membrane-bound form of IL-17A promotes the growth and tumorigenicity of
cancer cells
Young Sang Kim
Chungnam National University, South Korea
I
nterleukin-17A is a member of the IL-17 family, and is known as CTLA8 in the mouse. It is produced by T lymphocytes and NK
cells and has proinflammatory roles, inducing cytokine and chemokine production. However, its role in tumor biology remains
controversial. We investigated the effects of locally produced IL-17A by transferring the gene, encoding it into mouse tumor cells
including B16 melanoma, and MethA fibrosarcoma, either in a secretory or a membrane-bound form. Expression of the membrane-
bound form on CT26 colon cancer cells dramatically enhanced their proliferation in
in vitro
. The enhanced growth was shown to be
due to an increased rate of cell cycle progression. After synchronizing cells by adding and withdrawing colcemid, the rate of cell cycle
progression in the cells expressing the membrane-bound form of IL-17A was much faster than that of the control cells. Both secretory
and membrane-bound IL-17A induced the expression of Sca-1 on the cancer cells, which is commonly associated with aggressive
phenotype of cancer cells. When tumor clones were grafted into syngeneic BALB/c mice, the tumor clones expressing the membrane-
bound form IL-17A grew rapidly; those expressing the secretory form also grew faster than the wild type CT26 cells, but slower than
the clones expressing the membrane-bound form. These results indicate that IL-17A promotes tumorigenicity, in part, by enhancing
cell cycle progression. This finding should be considered in treating tumors and immune-related diseases.
Biography
Young Sang Kim is a Professor in Biochemistry Department in Chungnam National University, finished his PhD at University of Illinois at Chicago and continued
Post-doctoral Research at Yale University for 2 years. His research interests focus is to develop a strategy for selective activation of tumor associated antigen (TAA)-
specific cytotoxic T lymphocytes. He evaluates anti-tumor effect of tumor cell vaccines engineered to express cytokines on tumor cell surface as a membrane-bound
form instead of the secretory form. In this way, he expects that the membrane-bound form of cytokine on tumor cells may function as a co-stimulatory molecule to
TAA-specific cytotoxic T lymphocytes. He has published more than 70 scientific papers in the last 20 years.
young@cnu.ac.krYoung Sang Kim, J Clin Cell Immunol 2017, 8:3(Suppl)
DOI: 10.4172/2155-9899-C1-037